AstraZeneca (LON:AZN) was downgraded by investment analysts at Jefferies Group from a “hold” rating to an “underperform” rating in a note issued to investors on Friday, AR Network reports.
AstraZeneca (LON:AZN) traded up 1.39% during mid-day trading on Friday, hitting GBX 3176.50. The stock had a trading volume of 1,996,682 shares. AstraZeneca has a 52-week low of GBX 2786.00 and a 52-week high of GBX 3544.50. The stock’s 50-day moving average is GBX 3215.42 and its 200-day moving average is GBX 3252.57. The company’s market cap is £39.770 billion.
A number of other firms have also recently commented on AZN. Analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,213 ($51.55) price target on the stock. Separately, analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,620 ($58.08) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, October 1st. They now have a GBX 3,300 ($52.94) price target on the stock. Twelve equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of GBX 3,100.38 ($49.74).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.